The identification of molecular agents inhibiting specific functions in cancer cells
progression is considered as one of the most successful plans in cancer treatment. The …

Targeted degradation of proteins by chimeric heterobifunctional degraders has emerged as
a major drug discovery paradigm. Despite the increased interest in this approach, the criteria …

Adult mammals are generally believed to have limited ability to regenerate complex tissues
and instead, repair wounds by forming scars. In humans and across mammalian species …

Aberrant glycosylation is a hallmark of a cancer cell. One prevalent alteration is an
enrichment in α2, 6-linked sialylation of N-glycosylated proteins, a modification directed by …

Monitoring the drug efficacy or resistance in vitro is usually carried out by measuring the
response of single few proteins. However, observation of single proteins instead of an …

Constitutive activation of the epidermal growth factor receptor (EGFR) because of somatic
mutations of the EGFR gene is commonly observed in tumors of non–small cell lung cancer …

In non‐small cell lung cancer (NSCLC), activating mutations in the epidermal growth factor
receptor (EGFR) induce sensitivity to EGFR tyrosine kinase inhibitors. Despite impressive …

EGFR signaling initiates upon ligand binding which leads to activation and internalization of
the receptor-ligand complex. Here, we evaluated if BUB1 impacted EGFR signaling by …

The discovery of activating epidermal growth factor receptor (EGFR) mutations spurred the
use of EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, as the first-line treatment of …

Purpose With the identification of epidermal growth factor receptor (EGFR) mutations in non–
small cell lung cancer (NSCLC) cells, EGFR–tyrosine kinase inhibitors (TKIs) are being used …